| ASSET | YEAR | % RETURN |
|---|---|---|
PCB Bancorp (PCB) | 2016 | -99.81% |
Kalvista Pharmaceuticals (KALV) | 2016 | -85.93% |
Zevra Therapeutics (ZVRA) | 2016 | -85.04% |
Novavax (NVAX) | 2016 | -84.58% |
XOMA (XOMA) | 2016 | -83.89% |
Dynavax Technologies (DVAX) | 2016 | -83.23% |
Tandem Diabetes Care (TNDM) | 2016 | -81.55% |
Savara (SVRA) | 2016 | -79.33% |
Calumet Specialty Products Partners (CLMT) | 2016 | -78.68% |
Gyre Therapeutics (GYRE) | 2016 | -77.43% |
Clearpoint Neuro (CLPT) | 2016 | -77.27% |
Lightbridge (LTBR) | 2016 | -76.97% |
Celldex Therapeutics (CLDX) | 2016 | -76.76% |
Community Health Systems (CYH) | 2016 | -73.48% |
Gevo (GEVO) | 2016 | -71.73% |
Pacific Biosciences of California (PACB) | 2016 | -70.75% |
Stagwell (STGW) | 2016 | -68.23% |
FuelCell Energy (FCEL) | 2016 | -68.18% |
Fubotv (FUBO) | 2016 | -66.67% |
Uniqure (QURE) | 2016 | -65.73% |
POET Technologies (POET) | 2016 | -65.71% |
Novocure (NVCR) | 2016 | -64.32% |
Teekay Tankers (TNK) | 2016 | -64.08% |
Harrow Health (HROW) | 2016 | -63.82% |
Eyepoint Pharmaceuticals (EYPT) | 2016 | -63.38% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
